Synbias Co-Owns Cancer Drug IP, Can't Be Sued, Judge Rules

Law360, New York (September 06, 2013, 8:52 PM ET) -- In an unusual case that required an interpretation of Ukrainian patent law to determine ownership of U.S. patents, a California federal judge has ruled that Synbias Pharma cannot be sued by Solux Corp. for infringing chemotherapy drug patents because Synbias co-owns them.

In the Aug. 30 decision, U.S. District Judge Marilyn Huff said that Solux, which is listed as a co-owners of the patents, lacks standing to sue Synbias for infringement because the patents were never properly transferred to Solux.

"In sum, Synbias was at least...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers


Case Information

Case Title

Synbias Pharma v. Solux Corporation

Case Number



California Southern

Nature of Suit



Marilyn L. Huff

Date Filed

December 29, 2011


Law Firms Mentioned